Lucy Gilbert

Chair

McGill University
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Purpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Patients and Methods: A total of 153 patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and 161 patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) EC were enrolled and dosed. Patients received 500 mg dostarlimab every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression. Primary endpoints were objective response rate (ORR) and duration of response (DOR). Results: A total of 143 patients with dMMR/MSI-H EC and 156 patients with MMRp/MSS EC were evaluated for efficacy. ORR was 45.5% (n = 65) and 15.4% (n = 24) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. Median DOR for dMMR/MSI-H EC was not met (median follow-up, 27.6 months); median DOR for MMRp/MSS EC was 19.4 months. The ORRs by combined positive score (CPS) ≥1 status were 54.9% and 21.7% for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORRs by high tumor mutational burden (≥10 mutations/Mb) were 47.8% (43/90) and 45.5% (5/11) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORR in TP53mut or POLεmut molecular subgroups was 18.1% (17/94) and 40.0% (2/5), respectively. The safety profile of dostarlimab was consistent with previous reports. Conclusions: Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab. See related commentary by Jangra and Dhani, p. 4521

Year:

2023

Year:

2023

Collaborators (9)

Laurence Bernard

McGill University Health Centre

CANADA
View details

Anna V. Tinker

The University of British Columbia

CANADA
View details

Joanne Alfieri

Associate professor and Associate Chair (Education)

McGill University Health Centre

CANADA
View details

Raanan Meyer

Cedars-Sinai Medical Center

UNITED STATES
View details

Reitan Ribeiro

Associate Professor, Division of Gynecologic Oncology

McGill University Health Centre

CANADA
View details

Basile Tessier-Cloutier

Assistant Professor

McGill University

CANADA
View details

Gabriel Levin

-

ISRAEL
View details

Anna Reyners

Professor in Palliative Medicine

University Medical Center Groningen

NETHERLANDS
View details

Shuk On Annie Leung

Scientist

Research Institute of the McGill University Health Centre

CANADA
View details